Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Gulley

Showing results (1-10 of 391) with videos related to

Pageof 40
Sort By:
Human Vaccines & Immunotherapeutics|September 22, 2012
Therapeutic vaccines: the ultimate personalized therapy?James L Gulley
Blood|August 25, 2012
Toward an off-the-shelf vaccine for B-cell malignanciesJames L Gulley
Cancer Cell|November 9, 2021
A rare insight into the immunosuppressive landscape of prostate cancer bone metastasesClaudia Palena, James L Gulley
Translational Lung Cancer Research|March 26, 2015
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancerArun Rajan, James L Gulley
Journal of the National Cancer Institute|January 12, 2021
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?Marijo Bilusic, James L Gulley
JAMA|November 13, 2018
Vaccines as an Integral Component of Cancer ImmunotherapyJeffrey Schlom, James L Gulley
Cancer Immunology, Immunotherapy : CII|November 29, 2011
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesMarijo Bilusic, James L Gulley
Translational Cancer Research|October 1, 2020
Infusion-related reactions with administration of avelumab: mild and manageable side effectsJames L Gulley, Karen Kelly
Journal of the National Cancer Institute|July 28, 2018
Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot"Marijo Bilusic, James L Gulley
Clinical Genitourinary Cancer|January 7, 2011
The current and emerging role of immunotherapy in prostate cancerRavi A Madan, James L Gulley
Pageof 40

Showing results (1-10 of 391) with videos related to

Sort By:
Pageof 40
Human Vaccines & Immunotherapeutics|September 22, 2012
Therapeutic vaccines: the ultimate personalized therapy?James L Gulley
Blood|August 25, 2012
Toward an off-the-shelf vaccine for B-cell malignanciesJames L Gulley
Cancer Cell|November 9, 2021
A rare insight into the immunosuppressive landscape of prostate cancer bone metastasesClaudia Palena, James L Gulley
Translational Lung Cancer Research|March 26, 2015
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancerArun Rajan, James L Gulley
Journal of the National Cancer Institute|January 12, 2021
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?Marijo Bilusic, James L Gulley
JAMA|November 13, 2018
Vaccines as an Integral Component of Cancer ImmunotherapyJeffrey Schlom, James L Gulley
Cancer Immunology, Immunotherapy : CII|November 29, 2011
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesMarijo Bilusic, James L Gulley
Translational Cancer Research|October 1, 2020
Infusion-related reactions with administration of avelumab: mild and manageable side effectsJames L Gulley, Karen Kelly
Journal of the National Cancer Institute|July 28, 2018
Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot"Marijo Bilusic, James L Gulley
Clinical Genitourinary Cancer|January 7, 2011
The current and emerging role of immunotherapy in prostate cancerRavi A Madan, James L Gulley
Pageof 40